Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02467478 · ClinicalTrials.gov registry record · Phase 4
Linagliptin's Effect on CD34+ Stem Cells
A Phase 4 study, sponsored by George Washington University.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
NCT02467478 is a Phase 4 study that has completed, run by George Washington University. The registered enrollment target is 31 participants.
The verdict
NCT02467478, a Phase 4 study, has completed, sponsored by George Washington University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
Study Summary
Type 2 diabetes is a national epidemic. Diabetes has undesirable effects on blood vessels which may contribute to heart disease. Endothelial Progenitor Cells (EPCs) are found in the blood. Research has shown that improving the survival of these special blood cells may decrease the harmful effects of diabetes on blood vessels and reduce or reverse heart disease. Linagliptin is an Food and Drug Administration (FDA) approved prescription medicine used along with insulin or with oral medications to lower blood sugar in people with Type 2 diabetes. It is in a class of diabetes medication called Dipeptidyl peptidase-4 (DPP-4) inhibitors. DPP-4 inhibitors have been shown to increase EPCs in patients with Type 2 diabetes. Hypothesis: Both type 2 diabetes and Chronic Kidney Disease (CKD) are associated with poor stem cell number and function. Poor viability and function of EPCs in CKD and diabetes The investigators hypothesize that use of Linagliptin (along with Insulin) may help reduce cardiovascular risk by improving EPC survival and function above and beyond adequate glucose metabolism control
Interventions
- DRUG Placebo
- DRUG Linagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2015-04 |
| Est. Completion | 2019-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02467478
The ClinicalTrials.gov registry entry for NCT02467478 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is George Washington University, which has 133 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02467478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02467478 about?
NCT02467478 is a clinical study titled "Linagliptin's Effect on CD34+ Stem Cells". Type 2 diabetes is a national epidemic. Diabetes has undesirable effects on blood vessels which may contribute to heart disease. Endothelial Progenitor Cells (EPCs) are found in the blood. Research has shown that improving the survival of these special blood cells may decrease the harmful effects of...
What is the current status of trial NCT02467478?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2015-04. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02467478?
The interventions under investigation include: Placebo (DRUG), Linagliptin (DRUG).
Who is sponsoring clinical trial NCT02467478?
This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.